CoRegen announced the close of a $93,390,000 million financing to advance CMC development
“We are delighted to have the support of our investors during this pivotal time of growth for the company,” said Suneet Varma, CoRegen’s newly appointed Chairman. “This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief we have a potentially paradigm-shifting solution in our master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers, including but not limited to triple negative breast cancer and glioblastoma, for which research to date hasn’t yet moved the needle in a meaningful way in many years. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines